摘要
目的探讨血清转化生长因子-β_(1)(TGF-β_(1))、白细胞介素-33(IL-33)在慢性乙型肝炎(CHB)患者病情评估中的应用价值。方法选取2019年1月至2021年1月兰考第一医院收治的84例CHB患者作为研究对象,评估患者病情程度,询问并记录患者一般资料,检测患者入院时血清TGF-β_(1)、IL-33水平并分析其与CHB患者病情程度的相关性。结果84例CHB患者中轻度肝纤维化31例(36.90%),中度肝纤维化34例(40.48%),重度肝纤维化19例(22.62%)。中、重度组肝纤维化患者占比高于轻度组,入院时血清TGF-β_(1)、IL-33水平高于轻度组,差异有统计学意义(P<0.05);中、重度组入院时血清TGF-β_(1)、IL-33水平比较,差异无统计学意义(P>0.05)。绘制受试者工作特征(ROC)曲线,结果显示,血清TGF-β_(1)、IL-33单独及联合检测评估中、重度CHB的曲线下面积(AUC)均>0.70,均有一定评估价值,其中联合检测价值最高。结论血清TGF-β_(1)、IL-33水平可有效评估CHB患者病情。
Objective To explore the value of serum transforming growth factor-β1(TGF-β1)and interleukin-33(IL-33)in the evaluation of disease severity of patients with chronic hepatitis B(CHB).Methods A total of 84 patients with CHB treated in the First Hospital of Lankao from January 2019 to January 2021 were selected as the research subjects.The degree of the patients’condition was evaluated,the baseline data were asked and recorded,the level of IL-33,TGF-β1 at admission and its correlation with the severity of CHB patients were analyzed.Results Among the 84 patients with CHB,there were 31 cases(36.90%)of mild hepatic fibrosis,34 cases(40.48%)of moderate hepatic fibrosis,and 19 cases(22.62%)of severe hepatic fibrosis.The proportion of patients with hepatic fibrosis in moderate group and severe group was higher than that in mild group,and the levels of serum TGF-β1 and IL-33 were higher than those in mild group,with statistical significant differences(P<0.05),there was no statistical significant difference in the levels of serum TGF-β1 and IL-33 at admission between moderate group and severe group(P>0.05).The receiver operating characteristic(ROC)curve was drawn,and the results showed that the area under curve(AUC)of serum TGF-β1 and IL-33 for single and combined detection in evaluating moderate,severe CHB were>0.70,all had certain evaluation value,among which the joint detection value was the highest.Conclusion The levels of serum TGF-β1 and IL-33 can effectively evaluate the disease severity of patients with CHB.
作者
张亚瑞
ZHANG Yarui(Department of Laboratory,the First Hospital of Lankao,Kaifeng 475300,China)
出处
《河南医学研究》
CAS
2021年第34期6513-6516,共4页
Henan Medical Research
